These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 2122481

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The effect of the thromboxane A2/prostaglandin endoperoxide receptor antagonist SQ 30,741 on myocardial infarct size and blood flow during myocardial ischemia and reperfusion.
    Grover GJ, Schumacher WA, Simon M, Parham C.
    J Cardiovasc Pharmacol; 1988 Dec; 12(6):701-9. PubMed ID: 2467089
    [Abstract] [Full Text] [Related]

  • 3. Myocardial salvage efficacy of a thromboxane receptor antagonist, SQ, 30,741, in relation to inhibition ex vivo of platelet function in the ferret.
    Gomoll AW, Ogletree ML.
    Prostaglandins; 1993 Sep; 46(3):233-42. PubMed ID: 8234831
    [Abstract] [Full Text] [Related]

  • 4. Antithrombotic effects of the thromboxane A2 antagonist, SQ 28,668, in vitro and in the coronary circulation in vivo.
    Ogletree ML, Harris DN, Heran CL, Phillips MB, Michel IM, Goldenberg HJ.
    Eicosanoids; 1988 Sep; 1(2):85-91. PubMed ID: 2856188
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of cyclic flow variations in stenosed canine coronary arteries by thromboxane A2/prostaglandin H2 receptor antagonists.
    Ashton JH, Schmitz JM, Campbell WB, Ogletree ML, Raheja S, Taylor AL, Fitzgerald C, Buja LM, Willerson JT.
    Circ Res; 1986 Nov; 59(5):568-78. PubMed ID: 3542279
    [Abstract] [Full Text] [Related]

  • 6. Effect of the thromboxane receptor antagonist SQ 29,548 on myocardial infarct size in dogs.
    Grover GJ, Schumacher WA.
    J Cardiovasc Pharmacol; 1988 Jan; 11(1):29-35. PubMed ID: 2450253
    [Abstract] [Full Text] [Related]

  • 7. The effect of the thromboxane A2 receptor antagonist SQ 29,548 on the severity of pacing-induced ischemia.
    Grover GJ, Schumacher WA.
    Basic Res Cardiol; 1989 Jan; 84(1):103-10. PubMed ID: 2522297
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. EP 171: a high affinity thromboxane A2-mimetic, the actions of which are slowly reversed by receptor blockade.
    Jones RL, Wilson NH, Lawrence RA.
    Br J Pharmacol; 1989 Apr; 96(4):875-87. PubMed ID: 2743082
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Endothelin-1-induced release of thromboxane A2 increases the vasoconstrictor effect of endothelin-1 in postischemic reperfused rat hearts.
    Zaugg CE, Hornstein PS, Zhu P, Simper D, Lüscher TF, Allegrini PR, Buser PT.
    Circulation; 1996 Aug 15; 94(4):742-7. PubMed ID: 8772697
    [Abstract] [Full Text] [Related]

  • 12. Combined administration of 5-HT2 and thromboxane A2 antagonists: effects on platelet aggregation and isolated cardiac muscle.
    Shaw LA, Batey AJ, Coker SJ.
    Br J Pharmacol; 1997 Jul 15; 121(5):875-82. PubMed ID: 9222543
    [Abstract] [Full Text] [Related]

  • 13. Protamine-induced pulmonary hypertension in heparinized monkeys and pigs is inhibited by the thromboxane receptor antagonist SQ 30,741.
    Schumacher WA, Heran CL, Ogletree ML.
    Eicosanoids; 1990 Jul 15; 3(2):87-93. PubMed ID: 2144979
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Desensitisation of human platelets against stimulation by thromboxane mimics--reduction in receptor capacity and loss of functional response.
    Thierauch KH, Gabriel D, Prior G, Schillinger E.
    Biomed Biochim Acta; 1988 Jul 15; 47(10-11):S75-8. PubMed ID: 2470362
    [Abstract] [Full Text] [Related]

  • 16. Pharmacological evidence for thromboxane receptor heterogeneity--implications for the eye.
    Krauss AH, Woodward DF, Burk RM, Gac TS, Gibson LL, Protzman CE, Abbass F, Marshall K, Senior J.
    J Ocul Pharmacol Ther; 1997 Aug 15; 13(4):303-12. PubMed ID: 9261766
    [Abstract] [Full Text] [Related]

  • 17. Characterization of binding of a specific antagonist, [3H]-SQ 29,548, to soluble thromboxane A2/prostaglandin H2 (TP) receptors in human platelet membranes.
    Monshizadegan H, Hedberg A, Webb ML.
    Life Sci; 1992 Aug 15; 51(6):431-7. PubMed ID: 1386132
    [Abstract] [Full Text] [Related]

  • 18. Antiaggregatory activity of 8-epi-prostaglandin F2 alpha and other F-series prostanoids and their binding to thromboxane A2/prostaglandin H2 receptors in human platelets.
    Yin K, Halushka PV, Yan YT, Wong PY.
    J Pharmacol Exp Ther; 1994 Sep 15; 270(3):1192-6. PubMed ID: 7932171
    [Abstract] [Full Text] [Related]

  • 19. Antagonism of thromboxane actions in the isolated perfused rat heart.
    Stahl GL, Darius H, Lefer AM.
    Life Sci; 1986 Jun 02; 38(22):2037-41. PubMed ID: 2940431
    [Abstract] [Full Text] [Related]

  • 20. Phenol red is a thromboxane A2/prostaglandin H2 receptor antagonist in canine lingual arteries and human platelets.
    Greenberg SS, Johns A, Kleha J, Xie J, Wang Y, Bianchi J, Conley K.
    J Pharmacol Exp Ther; 1994 Mar 02; 268(3):1352-61. PubMed ID: 8138950
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.